Portal de Periódicos da CAPES

Neuroendocrine and Electroencephalographic Sleep Changes Due to Acute Amphetamine Ingestion in Human Beings

1976; Karger Publishers; Volume: 22; Issue: 1 Linguagem: Inglês

10.1159/000122612

1423-0194

Carlos Valverde-R, L.S. Pastrana, Jorge Alejandro Cebada Ruíz, Herrera Arturo Solís, José Luis Parra Jurado, C.M. Sordo, Augusto Fernández‐Guardiola, J Maisterrena,

Regulation of Appetite and Obesity

Amphetamine, a clinically used sympathomimetic central-acting drug, was administered in Spansule capsules in a blind schedule to 8 normal obse volunteers in a daily (8 a.m.) single 15 dose for 7 days. The study, conducted in the metabolic ward, included two 7 day placebo periods (pre- and post-drug). During the 1st placebo period, all subjects exhibited within the 1st 2 h of sleep a clear and significant nocturnal increase of growth hormone (GH) closely related with sleep stages 3 and 4. Thyrotropin (TSH) increase was observed between 01.00 to 04.00 h and was accompanied by a reduction of thyroxine (T4) levels. Cortisol levels presented their characteristic rhythm, clearly associated with paradoxical sleep (REM). Amphetamine significantly reduced stages 3 and 4, as well as REM sleep, and increased stage 2. GH and cortisol circadian profiles were preserved, although their magnitude was diminished. The extent of nocturnal TSH and T4 changes was significantly reduced. Drug withdrawal was accompanied by a rebound of REM sleep and a trend to recover the pretreatment TSH and T4 temporal profile. These results suggest that adrenergic neurotrasmitters may be a significant modulating system for TSH and cortisol, whereas GH nocturnal secretion may be influenced by different mechanisms.